We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUnicorn Asset Management Regulatory News (UAV)

Share Price Information for Unicorn Asset Management (UAV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 91.50
Bid: 88.00
Ask: 95.00
Change: 0.00 (0.00%)
Spread: 7.00 (7.955%)
Open: 91.50
High: 91.50
Low: 91.50
Prev. Close: 91.50
UAV Live PriceLast checked at -
Unicorn AIM VCT is an Investment Trust

To provide shareholders with an attractive return from a diversified portfolio, predominantly invested in the shares of AIM quoted companies by maintaining dividend distributions to shareholders.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Voluntary Interim Management Statement

14 Jan 2019 13:28

RNS Number : 0389N
Unicorn AIM VCT PLC
14 January 2019
 

Unicorn AIM VCT plc ("the Company")

Interim Management Statement 

For the period from 1 October 2018 to 31 December 2018

 

Introduction

This voluntary Interim Management Statement (IMS) covers the three month period ended 31 December 2018, together with relevant information up to the date of publication. 

 

Investment Objective

The Company's objective is to provide Shareholders with an attractive return from a diversified portfolio of investments, predominantly in the shares of AIM quoted companies, by maintaining a steady flow of dividend distributions to Shareholders from the income as well as capital gains generated by the portfolio.

 

It is also the objective that the Company should continue to qualify as a Venture Capital Trust, so that Shareholders benefit from the taxation advantages that this brings. To achieve this at least 70% (80% for accounting periods commencing after 5 April 2019) of the Company's total assets are to be invested in qualifying investments of which 70% by VCT value (30% in respect of investments made before 6 April 2018 from funds raised before 6 April 2011) must be in ordinary shares which carry no preferential rights (save as permitted under VCT rules) to dividends or return of capital and no rights to redemption.

 

Performance

The period under review has been an extremely challenging one for UK equity markets. Uncertainty surrounding the outcome of Brexit negotiations, an escalating trade war between the US and China, concerns over a slowdown in the Chinese economy and deteriorating financial results from some of the world's most highly valued quoted companies, led to a rapid reversal in investor sentiment. In the UK, a combination of weak consumer spending, over-supply in the retail sector and a number of high profile corporate insolvencies exacerbated the sharp sell-off in equities. The short term health of the UK economy appears dependent on securing a successful deal with the European Union, which, in itself, now seems in doubt.

 

In the past three months, the largest declines in value have generally been experienced by smaller quoted companies. In total return terms, since the start of October 2018, the FTSE AIM All-Share Index has fallen by 21.5%, while the Numis Smaller Companies Index (including AIM) has declined by 14.6%. The FTSE 250 Index fell by 13.3% over the same period, while the FTSE 100 Index declined by 9.6%.

 

Your Company has not been immune from the wider market turmoil. Although performance in the period was not specifically impacted by profit warnings from any of our investee companies, the value of the portfolio as a whole nonetheless experienced a meaningful decline.

 

In the three month period ended 31 December 2018, Net Asset Value fell from 171.8 pence per share at the start of the period to 141.7 pence per share as at 31 December 2018, a decline of 17.5%. Of the 79 VCT qualifying investments held in the portfolio, the majority recorded share price declines during the period under review. Of these, eight investments generated unrealised capital losses in excess of £1 million each. The performance of the non-qualifying investments was similarly impacted by the general malaise in equity markets during the period under review.

 

At 31 December 2018, an estimated 80.5% of total assets were invested in VCT qualifying companies.

 

Material Transactions

During the period under review, six VCT qualifying investments were made at a total cost of nearly £3 million. Of these investments, two were in businesses new to the portfolio, while four were in the form of follow-on funding.

In aggregate, almost £2.5 million was raised from the partial disposal of a number of holdings during the period. The purpose of such disposals is threefold; to ensure stock specific risk is contained, to lock in capital profits for future distribution to Shareholders via dividend payments and to help manage liquidity requirements. Two further investments; Communisis and Sinclair Pharma, were acquired by trade buyers during the period realising total proceeds of £2.3 million and a capital gain on investment of £0.5m. A holding in Science Group was also fully realised, raising £1.0 million and crystallising a capital gain of £0.8m.

Top Ten VCT Qualifying Holdings as at 31 December 2018

Stock

% of fund

Abcam

8.6

Tracsis

5.9

Mattioli Woods

3.9

Hasgrove

3.9

Interactive Investor

3.8

Anpario

3.7

City Pub Group

3.5

MaxCyte

3.1

Cohort

2.7

Tristel

2.4

Total

41.5%

 

Share Buy-Backs

During the period from 1 October 2018 to 31 December 2018, the Company bought back 407,205 of its own Ordinary Shares for cancellation, at an average price of 129.6 pence per share including costs. As at 31 December 2018, there were 116,818,843 Ordinary Shares in issue.

 

 

 

 

Dividends

The Board has recommended a final dividend of 3.5 pence per share for the financial year ended 30 September 2018. The proposed dividend was approved by Shareholders at the Company's Annual General Meeting, which was held on 10 January 2019, and will be paid on 1 February 2019 to Shareholders on the register on 11 January 2019. Total dividends paid in respect of the financial year ended 30 September 2018, will therefore amount to 6.5 pence per share (2017: 6.5 pence per share).

 

Material Events

On 20 December 2018, the Directors announced that they intend to launch an offer for subscription to raise £15 million (with an over-allotment facility to raise up to a further £10 million) through the issue of new ordinary shares ("the Offer"). The prospectus, which will contain the full details and terms and conditions of the Offer, is expected to be available at the end of January 2019.

 

There were no other material events during the period from 1 October 2018 to 31 December 2018.

 

We remain confident that we have a well diversified portfolio of interesting companies of varying maturities. While stock markets may well remain volatile in the short term, we are cautiously optimistic that, once the outcome of the Brexit negotiations becomes clear, the portfolio performance should become more positive.

 

Chris Hutchinson

Unicorn Asset Management

Investment Manager

 

14 January 2019

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCZMGMMFDKGLZM
Date   Source Headline
8th Apr 20241:46 pmRNSNet Asset Value(s)
2nd Apr 202410:46 amRNSTotal Voting Rights
18th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 202412:00 pmRNSDirector/PDMR Shareholding
11th Mar 202411:59 amRNSTotal Voting Rights
11th Mar 202411:57 amRNSIssue of Equity
7th Mar 202411:34 amRNSNet Asset Value(s)
1st Mar 202410:54 amRNSTotal Voting Rights
15th Feb 20244:30 pmRNSOffer for Subscription Update
14th Feb 20241:36 pmRNSDirector/PDMR Shareholding
14th Feb 202410:23 amRNSIssue of Equity
8th Feb 20243:47 pmRNSOffer for Subscription - Update
7th Feb 20245:43 pmRNSResult of AGM
5th Feb 20243:37 pmRNSNet Asset Value(s)
1st Feb 20242:53 pmRNSInterim Management Statement
26th Jan 202411:47 amRNSOffer for Subscription and Issue of Prospectus
11th Jan 20247:00 amRNSDividend Declaration
9th Jan 202410:39 amRNSNet Asset Value(s)
20th Dec 20233:06 pmRNSDirector Declaration
8th Dec 20237:00 amRNSFinal Results
6th Dec 20233:47 pmRNSNet Asset Value(s)
28th Nov 202310:00 amRNSIntention to launch an Offer
6th Nov 20234:48 pmRNSNet Asset Value(s)
17th Oct 20235:04 pmRNSNet Asset Value(s)
2nd Oct 20239:19 amRNSTotal Voting Rights
25th Sep 20239:18 amRNSTransaction in Own Shares
7th Sep 202311:40 amRNSNet Asset Value(s)
1st Sep 202311:39 amRNSTotal Voting Rights
25th Aug 20239:16 amRNSTransaction in Own Shares
14th Aug 202312:42 pmRNSDirector/PDMR Shareholding
11th Aug 20231:47 pmRNSIssue of Equity under Dividend Reinvestment Scheme
4th Aug 202310:57 amRNSNet Asset Value(s)
1st Aug 202310:19 amRNSTotal Voting Rights
19th Jul 20237:00 amRNSTransaction in Own Shares
7th Jul 20239:12 amRNSNet Asset Value(s)
3rd Jul 202312:23 pmRNSTotal Voting Rights
9th Jun 20234:11 pmRNSTransaction in Own Shares
6th Jun 20232:18 pmRNSHolding(s) in Company
5th Jun 20234:43 pmRNSNet Asset Value(s)
31st May 20237:00 amRNSHalf-year Report
5th May 20239:20 amRNSNet Asset Value(s)
6th Apr 202310:53 amRNSNet Asset Value(s)
3rd Apr 202310:25 amRNSTotal Voting Rights
10th Mar 20234:32 pmRNSTransaction in Own Shares
3rd Mar 20235:36 pmRNSNet Asset Value(s)
1st Mar 20239:52 amRNSTotal Voting Rights
22nd Feb 20234:04 pmRNSDirector/PDMR Shareholding
22nd Feb 20239:14 amRNSIssue of Equity
21st Feb 202311:43 amRNSNet Asset Value(s)
14th Feb 202312:42 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.